Literature DB >> 20230815

Structural changes and inhibition of sucrase after binding of scopolamine.

Dariush Minai-Tehrani1, Negar Fooladi, Saeed Minoui, Zahra Sobhani-Damavandifar, Tooka Aavani, Soraya Heydarzadeh, Farnoosh Attar, Mina Ghaffari, Habibollah Nazem.   

Abstract

Scopolamine (hyoscine) is commonly used as an anticholinergic drug to relieve nausea, vomiting and dizziness of a motion sickness as well as recovery from anesthesia and surgery. Sucrase as a hydrolytic enzyme breaks down sucrose into its monomers, glucose and fructose. The aim of this study was to evaluate the effect of scopolamine on the activity and the structural changes of yeast sucrase. The results showed that binding of scopolamine to sucrase could inhibit the enzyme activity. A non-competitive inhibition was observed in different concentrations of scopolamine (0.6 to 3.6mM). The study by circular dichroism measurement in far-UV showed that the absolute enzyme exhibited a flat negative trough, indicating the presence of alpha-helices and beta-sheet structures in the enzyme. Binding of the inhibitor on the enzyme made a deeper trough at 218nm, suggesting the increasing of beta-sheet content of the enzyme. Fluorescence measurement showed that binding of scopolamine to free enzyme and enzyme-substrate complex increased the peak intensity at 350nm and also induced red shift. Our findings suggest that scopolamine binds to the location other than the active site of enzyme and that the binding causes structural changes and inhibits the enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230815     DOI: 10.1016/j.ejphar.2010.02.040

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Functional and structural changes of human erythrocyte catalase induced by cimetidine: proposed model of binding.

Authors:  Fatemeh Yazdi; Dariush Minai-Tehrani; Mahboubeh Jahngirvand; Ali Almasirad; Zahra Mousavi; Masoudeh Masoud; Hamidreza Mollasalehi
Journal:  Mol Cell Biochem       Date:  2015-03-05       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.